Caligan Partners LP
CIK 1727492 · Holdings on Sep 30, 2023 · First reported Nov 14, 2023
Top ten holdings
Q3 2023- LQDA29.98%
- 01625920226.69%
- LAB11.31%
- ANIK10.30%
- EXEL10.18%
- EOLS7.87%
- VRNA1.53%
- ADMA1.09%
- VRCA0.52%
- RAH0.41%
Share classes counted separately99.88%
Portfolio value by quarter
Top 10 holdings 12
USD · B = billion · M = million; expand a row for exact values| # | Security | Value | Weight | Quantity | Weight / quantity change | Activity | |
|---|---|---|---|---|---|---|---|
| 01 | LQDALIQUIDIA CORPCOM NEW View history and evidence | $58.60M | 29.98% | 9.24M shares | — | ↗▾ | |
| 02 | 016259202ALIMERA SCIENCES INCCOM NEW View history and evidence | $52.19M | 26.69% | 16.84M shares | — | ↗▾ | |
| 03 | LABSTANDARD BIOTOOLS INC View history and evidence | $22.10M | 11.31% | 7.62M shares | — | ↗▾ | |
| 04 | ANIKANIKA THERAPEUTICS INC View history and evidence | $20.15M | 10.30% | 1.08M shares | — | ↗▾ | |
| 05 | EXELEXELIXIS INC View history and evidence | $19.90M | 10.18% | 910.73K shares | — | ↗▾ | |
| 06 | EOLSEVOLUS INC View history and evidence | $15.39M | 7.87% | 1.68M shares | — | ↗▾ | |
| 07 | VRNAVERONA PHARMA PLC - ADRSPONSORED ADS View history and evidence | $2.98M | 1.53% | 183.06K shares | — | ↗▾ | |
| 08 | ADMAADMA BIOLOGICS INC View history and evidence | $2.14M | 1.09% | 597.51K shares | — | ↗▾ | |
| 09 | VRCAVERRICA PHARMACEUTICALS INC View history and evidence | $1.01M | 0.52% | 259.59K shares | — | ↗▾ | |
| 10 | RAHSOCIETAL CDMO INC View history and evidence | $794.19K | 0.41% | 1.69M shares | — | ↗▾ |
Options overlay 1
$22.25M notionalPut and Call positions are separate. Notional is based on underlying securities, not option premium, market value or net exposure. Quantities are underlying shares.
| Security | Put / Call | Underlying shares | Notional | Quantity change | |
|---|---|---|---|---|---|
45845P958INTERCEPT PHARMACEUTICALS INCPUT View history and evidence | Put | 1.20M | $22.25M | ▾ |
1 / 1 options · preview only
Exited positions 2
| Security | Type | Shares out | Value out | Previous filing | This filing |
|---|---|---|---|---|---|
| ICPT INTERCEPT PHARMACEUTICALS IN | Non-derivative | — | — | SEC filing ↗ | |
| EYPT EYEPOINT INC | Non-derivative | — | — | SEC filing ↗ |
2 / 2 preview exits. Up to 30 exit records are previewed. Exit means absent from the current filing; execution date, price and proceeds are unknown.
Every number has a source.
CIK 1727492 · Period 2023-09-30
Data loaded 2026-09-23 · First reported 2023-11-14
Amendments and versions
{
"amendments_merged": null,
"prior_versions": null,
"cover_table_value": 217755783
}Take these holdings further.
This page includes 13 of 13 reported holdings. Sign in to look up the full history beyond 3 years, use advanced screening & filtering, download CSV, and get the complete set through the Akkru API.
- Download CSV
- Earlier quarters
- Advanced screening & filtering
- API & AI access
＋ New accounts get free API credits to explore data beyond ownership filings.
For AI agents & developers
The initial HTML of this page carries its exact data as script#portfolio-data (JSON): values, units, scope, preview limits and SEC sources. Read it directly, no script or API key needed; script#research-access says what needs an account. This page lists 13 of 13 current positions (options included); totals and weights use the complete filing.
Without an account: the last 3 years, with the row caps stated on the page. A free account opens all history on file on these pages and the CSV of what a page shows. Rows beyond the caps and bulk retrieval go through the authenticated API / MCP.
MCP https://api.akkrudata.ai/mcp
get_institutional_portfolio
{"cik":"1727492","quarter":"2023Q3","page_size":100}
get_institutional_manager_history
{"cik":"1727492","page_size":100}Connect to MCP with OAuth and follow the returned pagination. Credits and usage limits depend on the account.
- MCP endpoint
- https://api.akkrudata.ai/mcp
- API / MCP documentation
- /documents
- llms.txt
- /llms.txt
Sources, coverage & how to read this data
Figures are as reported to the SEC and merged with later amendments where Akkru could match them. Preview limits apply to what is listed, not to the totals, which come from the complete reported data. Nothing is zero-filled: a missing quarter or month is shown as missing.